Get the Stockscreener App
3.33
0.91%
0.03
After Hours:
3.34
0.010
+0.30%
Arbutus Biopharma Corp Stock (ABUS) Forecast
The Arbutus Biopharma Corp (ABUS) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $3.4078, representing a +2.34% increase from the current price of $3.33. The highest analyst price target is $3.918, and the lowest is $2.8977.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month ABUS Price Target
Average 5.316
(+59.64% Upside)
Is Arbutus Biopharma Corp (ABUS) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 49.71 | Neutral |
| STOCH(9,6) | 70.31 | Neutral |
| STOCHRSI(14) | 61.75 | Neutral |
| MACD(12,26) | -0.0136 | Buy |
| ADX(14) | 14.48 | Neutral |
| William %R | -36.51 | Neutral |
| CCI(14) | 28.27 | Neutral |
Buy: 1
Sell: 0
Neutral: 6
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
3.308
Buy
|
3.3218
Buy
|
| MA20 |
3.307
Buy
|
3.3197
Buy
|
| MA50 |
3.3844
Sell
|
3.4137
Sell
|
| MA100 |
3.6818
Sell
|
3.504
Sell
|
| MA200 |
3.5197
Sell
|
3.3608
Sell
|
Buy: 4
Sell: 6
Neutral: 0
Summary: Sell
According to our latest analysis, ABUS could be considered a Neutral, with 17 technical analysis indicators signaling 5 Buy signals, 6 signaling Sell signals and 6 Neutral signals. This suggests that investors should exercise caution when entering new positions on ABUS, as the market is likely to remain volatile in the near term.
- RSI (Relative Strength Index): The RSI(14) value of 49.71 indicates that ABUS is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 70.31 indicates that ABUS is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 61.75 indicates that ABUS is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 14.48 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 28.27 indicates that ABUS is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term ABUS price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Arbutus Biopharma Corp financial reports and earnings history, Arbutus Biopharma Corp (ABUS) stock could reach $3.1904 by 2030, $4.2923 by 2040 and $5.5351 by 2050. See the projected annual prices until 2050 of the Arbutus Biopharma Corp stock below:
- Arbutus Biopharma Corp (ABUS) is expected to reach an average price of $2.6647 in 2035, with a high prediction of $2.7644 and a low estimate of $2.4944. This indicates an $-19.98% rise from the last recorded price of $3.33.
- Arbutus Biopharma Corp (ABUS) stock is projected to chart a bullish course in 2040, with an average price target of $3.6839, representing an $10.63% surge from its current level. The forecast ranges from a conservative $3.6439 to a sky-high $4.2923.
- Our analysts predict Arbutus Biopharma Corp (ABUS) to jump 3.66% by 2045, soaring from $3.3903 to an average price of $3.4517, potentially reaching $3.9796. While $3.3903 is the low estimate, the potential upside is significant.
- Arbutus Biopharma Corp (ABUS) stock is expected to climb by 2050, reaching an average of $4.9578, a $48.88% jump from its current level. However, a wide range of estimates exists, with high and low targets of $5.5351 and $4.5869, respectively, highlighting the market's uncertainty.
Arbutus Biopharma Corp Stock (ABUS) Year by Year Forecast
Arbutus Biopharma Corp Stock (ABUS) Price Forecast for 2025
Arbutus Biopharma Corp Stock (ABUS) is expected to reach an average price of $5.316 in 2025, with a high prediction of $9.3825 and a low estimate of $1.2494. This indicates an +59.64% rise from the last recorded price of $3.33.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| March, 2025 | $3.1982 | $2.8977 | $3.918 | -3.96% |
| April, 2025 | $1.4091 | $1.3791 | $3.6084 | -57.69% |
| May, 2025 | $1.5782 | $1.2494 | $1.6098 | -52.61% |
| June, 2025 | $2.4605 | $1.3801 | $2.5405 | -26.11% |
| July, 2025 | $2.2814 | $1.9712 | $3.0507 | -31.49% |
| August, 2025 | $2.2221 | $2.1419 | $2.5616 | -33.27% |
| September, 2025 | $4.1528 | $2.0723 | $9.3825 | +24.71% |
| October, 2025 | $2.8037 | $2.6937 | $4.333 | -15.80% |
| November, 2025 | $3.4944 | $2.6739 | $3.754 | +4.94% |
| December, 2025 | $3.1853 | $3.1352 | $3.8048 | -4.34% |
Arbutus Biopharma Corp Stock (ABUS) Price Forecast for 2026
The predicted value for Arbutus Biopharma Corp (ABUS) in 2026 is set at an average of $4.5187. Estimates vary from a peak of $6.2367 to a trough of $2.8007, indicating an +35.70% surge from the present price of $3.33.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $4.706 | $3.0855 | $4.926 | +41.32% |
| February, 2026 | $4.7467 | $3.7666 | $6.2367 | +42.54% |
| March, 2026 | $4.2775 | $3.7973 | $4.8575 | +28.45% |
| April, 2026 | $4.7583 | $3.9467 | $5.5082 | +42.89% |
| May, 2026 | $4.0191 | $3.2787 | $4.9235 | +20.69% |
| June, 2026 | $3.6698 | $3.4894 | $4.0692 | +10.20% |
| July, 2026 | $2.9907 | $2.8007 | $3.9503 | -10.19% |
| August, 2026 | $3.6514 | $2.9408 | $3.8614 | +9.65% |
| September, 2026 | $3.2923 | $3.1623 | $4.1919 | -1.13% |
| October, 2026 | $3.383 | $2.9074 | $3.493 | +1.59% |
| November, 2026 | $3.8037 | $3.1533 | $3.9037 | +14.22% |
| December, 2026 | $4.6646 | $3.694 | $5.1146 | +40.08% |
Arbutus Biopharma Corp Stock (ABUS) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Arbutus Biopharma Corp (ABUS) is $4.5938, with a high forecast of $6.8765 and a low forecast of $2.3112. This indicates an +37.95% increase from the last price of $3.33.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $4.4003 | $4.1049 | $4.7899 | +32.14% |
| February, 2027 | $3.676 | $3.616 | $4.5356 | +10.39% |
| March, 2027 | $4.6569 | $3.3864 | $6.8765 | +39.85% |
| April, 2027 | $3.6876 | $3.5026 | $4.8771 | +10.74% |
| May, 2027 | $3.3983 | $2.758 | $3.6878 | +2.05% |
| June, 2027 | $3.1892 | $3.1492 | $4.019 | -4.23% |
| July, 2027 | $3.3599 | $3.0694 | $3.5694 | +0.90% |
| August, 2027 | $2.9406 | $2.8306 | $3.6003 | -11.69% |
| September, 2027 | $2.8615 | $2.3112 | $3.0608 | -14.07% |
| October, 2027 | $3.0622 | $2.6722 | $3.2021 | -8.04% |
| November, 2027 | $3.2329 | $2.9026 | $3.3729 | -2.91% |
| December, 2027 | $2.8838 | $2.5737 | $3.2331 | -13.40% |
Arbutus Biopharma Corp Stock (ABUS) Price Forecast for 2028
In 2028, Arbutus Biopharma Corp (ABUS) is projected to reach an average price of $2.8853, with a high projection of $3.5356 and a low estimate of $2.2351. This indicates an -13.35% fall from the last price of $3.33.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $2.5945 | $2.5345 | $2.934 | -22.09% |
| February, 2028 | $2.2953 | $2.2351 | $2.8249 | -31.07% |
| March, 2028 | $2.7261 | $2.2454 | $2.816 | -18.13% |
| April, 2028 | $3.0569 | $2.6963 | $3.2967 | -8.20% |
| May, 2028 | $2.7777 | $2.6472 | $3.1946 | -16.58% |
| June, 2028 | $3.1485 | $2.5381 | $3.3157 | -5.45% |
| July, 2028 | $3.0792 | $3.0642 | $3.419 | -7.53% |
| August, 2028 | $3.1901 | $2.9597 | $3.4149 | -4.20% |
| September, 2028 | $3.2608 | $3.1162 | $3.5356 | -2.08% |
| October, 2028 | $2.9915 | $2.8115 | $3.4286 | -10.17% |
| November, 2028 | $2.9724 | $2.802 | $3.112 | -10.74% |
| December, 2028 | $2.6931 | $2.5831 | $3.0576 | -19.13% |
Arbutus Biopharma Corp Stock (ABUS) Price Forecast for 2029
The 2029 price forecast for Arbutus Biopharma Corp Stock (ABUS) is $2.8889 on average, with a high prediction of $3.6913 and a low estimate of $2.0865. This represents an -13.25% decrease from the previous price of $3.33.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $2.564 | $2.5038 | $2.7283 | -23.00% |
| February, 2029 | $2.4247 | $2.3745 | $2.6042 | -27.19% |
| March, 2029 | $2.4354 | $2.3949 | $2.6054 | -26.86% |
| April, 2029 | $2.2561 | $2.1261 | $2.4458 | -32.25% |
| May, 2029 | $2.167 | $2.0865 | $2.3268 | -34.92% |
| June, 2029 | $2.4277 | $2.0972 | $2.4877 | -27.10% |
| July, 2029 | $2.8984 | $2.3781 | $2.9484 | -12.96% |
| August, 2029 | $2.7693 | $2.609 | $3.0286 | -16.84% |
| September, 2029 | $3.32 | $2.6645 | $3.36 | -0.30% |
| October, 2029 | $2.9009 | $2.8209 | $3.3591 | -12.89% |
| November, 2029 | $3.1216 | $2.7013 | $3.6913 | -6.26% |
| December, 2029 | $3.04 | $3.01 | $3.49 | -8.71% |
Arbutus Biopharma Corp Stock (ABUS) Price Forecast for 2030
Arbutus Biopharma Corp Stock (ABUS) is expected to reach an average price of $2.9486 in 2030, with a high forecast of $4.3639 and a low forecast of $1.5334. This signifies an -11.45% decrease from the last price of $3.33.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $2.1768 | $2.1518 | $3.1904 | -34.63% |
| February, 2030 | $3.0982 | $2.1471 | $3.4371 | -6.96% |
| March, 2030 | $2.3496 | $2.2646 | $3.1536 | -29.44% |
| April, 2030 | $2.0661 | $1.9961 | $2.465 | -37.96% |
| May, 2030 | $2.2378 | $2.0164 | $2.5968 | -32.80% |
| June, 2030 | $1.5893 | $1.5334 | $2.2482 | -52.27% |
| July, 2030 | $2.231 | $1.5825 | $2.3907 | -33.00% |
| August, 2030 | $3.6325 | $2.2414 | $3.6925 | +9.08% |
| September, 2030 | $3.7059 | $3.1535 | $4.3639 | +11.29% |
| October, 2030 | $4.0657 | $3.2553 | $4.1957 | +22.09% |
| November, 2030 | $2.8221 | $2.8171 | $4.276 | -15.25% |
| December, 2030 | $1.6555 | $1.6285 | $3.0178 | -50.28% |
3.95%
2.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):